2 years ago
Nodus Oncology Secures £2.4 Million for DNA Damage Response Target Inhibition
Nodus Oncology, a UK-based biotech company focused on developing molecules that inhibit novel DNA damage response (DDR) targets, has raised £2.4 million in funding led by KHAN Technology Transfer Fund I and Cumulus Oncology
The company plans to use the funds to accelerate the development of its PARG program, continue developing novel DDR targets, and expand its portfolio.
ProblemHealthcare
"Cancer cells rely on a complex network of DNA repair pathways to survive and multiply. Current cancer treatments often target these pathways, but some cancers become resistant. Nodus Oncology is developing new treatments that target a specific protein involved in DNA repair called PARG, which is essential for cancer cells to survive, but not for normal cells. This approach aims to overcome resistance to existing cancer treatments."
Solution
"Nodus Oncology has developed a new molecule that specifically targets and inhibits PARG. By blocking PARG, Nodus's treatment aims to disrupt DNA repair in cancer cells and make them more vulnerable to existing therapies. This innovative approach holds the potential to revolutionize cancer treatment by tackling resistant cancers and improving patient outcomes."
